Press Releases

Essex Bio-Technology Ltd today announced the interim results for the six months ended 30 June 2023. Financial Performance Returned to Pre-COVID-19 Operating Level During the period under review, the Group achieved a consolidated revenue of approximately HK$899 million, with an increase of 37.1% as compared to the same period last year, indicating normalcy in business to the pre-COVID-19 operating level. The profit of the Group increased by 22.0% to approxi

The National Institutes of Health the US’s medical research agency, selected Exothera S.A., a full-service Contract Development and Manufacturing Organization specialized in gene therapy, vaccines, oncolytic viruses, and nucleic acid-based therapeutics, to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2. As part of the Cooperative Research and Development Agreement, CRADA, they will be joined by researchers from Dartmouth Health’s Dartmouth

SSI Strategy a leading Life Sciences consultancy, today announced that it has entered into a definitive agreement to acquire NDA Group AB a leading regulatory affairs and drug development consultancy. This strategic combination will create a premier consultancy, specializing in guiding drug development companies from concept to commercialization, helping optimize the development process and maximize the therapeutic value of complex and novel treatments. The merger marks an

CPHI, the world's largest pharmaceutical event – spanning the entire supply chain from ingredients and finished dosages to machinery, bio, and packaging – returns to Fiera Milano (Rho) in 2024, October 8-10. The global pharma exhibition, organised by Informa, will be hosted in the city of Milan for the second time in three years in recognition of the massive pharmaceutical ingredients and manufacturing industry in the region. Italy is one of Europe’s

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma” SEHK: 3692.HK), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectio

CAS, a division of the American Chemical Society specializing in scientific information solutions, and Molecule.one, the biotechnology leader in AI-based solutions for pharmaceutical chemistry, established a strategic collaboration aimed at jointly developing computer-aided synthesis design technologies to accelerate scientific advances in early-stage drug discovery and help chemists discover new small molecules. Leveraging your existing technologies and expertise, including Molecul

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has filed a new provisional patent application with the United States Patent and Trademark Office (‘USPTO’) entitled “NSAID Formulation and Method” related to its E

Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11),[1] for the imaging of prostate cancer using positron emission tomography (PET). The Phase III Illuccix China study (ClinicalTrials.gov ID: NCT05847348) is a prospective, open-label, single-arm, multicenter study in Chinese patients with biochemically recurrent (BCR) prostate cancer that is intended to b

The summit brings together leading pharmaceutical marketing executives and innovative sponsors in an exclusive networking environment. The event's content is designed to address key challenges and interests in pharma marketing, as well as showcase relevant market developments and practical, progressive ideas and strategies employed by successful pioneers in the field. Participants at the summit will have the opportunity to pre-schedule one-on-one in-person business meetings with

The Medical Affairs Summit is scheduled to take place on 12 - 13 October 2023 at the luxurious Encore Boston Harbor in Boston, MA, US. The event brings together key Clinical Trial Executives representing pharmaceutical industries in the Americas. The Summit offers a highly focused and interactive platform for attendees to address core concerns and find solutions tailored to their specific needs. The Summit offers the opportunity for one-on-one business meetings, which allows sponsor